FOLD Stock Overview
A biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Amicus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.61 |
| 52 Week High | US$14.57 |
| 52 Week Low | US$9.02 |
| Beta | 0.69 |
| 11 Month Change | 15.18% |
| 3 Month Change | 10.78% |
| 1 Year Change | -8.22% |
| 33 Year Change | 2.02% |
| 5 Year Change | 16.92% |
| Change since IPO | -19.54% |
Recent News & Updates
Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector
Aug 16Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues
Jul 02
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt
Jun 06Amicus Therapeutics: Too Cheap At Under $10 A Share
May 20Recent updates
Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector
Aug 16Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues
Jul 02Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt
Jun 06Amicus Therapeutics: Too Cheap At Under $10 A Share
May 20Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough
Mar 27Amicus Therapeutics: Expect Improved Commercial Momentum In 2024
Feb 29Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk
Dec 19Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Jul 06Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors
May 14Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?
Mar 23We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt
Dec 06Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Aug 25Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding
Aug 10Amicus Therapeutics Q2 2022 Earnings Preview
Aug 03Is Amicus Therapeutics (NASDAQ:FOLD) Weighed On By Its Debt Load?
May 06Amicus Therapeutics: An Inflection Point In Growth
Apr 27Shareholder Returns
| FOLD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.5% | -0.2% | 0.5% |
| 1Y | -8.2% | 14.0% | 22.7% |
Return vs Industry: FOLD underperformed the US Biotechs industry which returned 14% over the past year.
Return vs Market: FOLD underperformed the US Market which returned 22.7% over the past year.
Price Volatility
| FOLD volatility | |
|---|---|
| FOLD Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FOLD has not had significant price volatility in the past 3 months.
Volatility Over Time: FOLD's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 517 | Brad Campbell | amicusrx.com |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.
Amicus Therapeutics, Inc. Fundamentals Summary
| FOLD fundamental statistics | |
|---|---|
| Market cap | US$3.44b |
| Earnings (TTM) | -US$119.54m |
| Revenue (TTM) | US$455.66m |
7.6x
P/S Ratio-28.8x
P/E RatioIs FOLD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FOLD income statement (TTM) | |
|---|---|
| Revenue | US$455.66m |
| Cost of Revenue | US$46.10m |
| Gross Profit | US$409.56m |
| Other Expenses | US$529.09m |
| Earnings | -US$119.54m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 89.88% |
| Net Profit Margin | -26.23% |
| Debt/Equity Ratio | 293.5% |
How did FOLD perform over the long term?
See historical performance and comparison